Federated Hermes’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $217M | Buy |
719,905
+32,089
| +5% | +$9.68M | 0.31% | 78 |
|
|
2026
Q1 | $228M | Buy |
687,816
+59,753
| +10% | +$20.3M | 0.37% | 60 |
|
|
2025
Q4 | $250M | Buy |
628,063
+77,959
| +14% | +$34.5M | 0.42% | 54 |
|
|
2025
Q3 | $251M | Buy |
550,104
+226,262
| +70% | +$92.1M | 0.44% | 44 |
|
|
2025
Q2 | $106M | Buy |
323,842
+59,669
| +23% | +$16.5M | 0.2% | 141 |
|
|
2025
Q1 | $71.3M | Buy |
264,173
+14,582
| +6% | +$3.75M | 0.15% | 172 |
|
|
2024
Q4 | $58.7M | Buy |
249,591
+80,668
| +48% | +$21.2M | 0.13% | 211 |
|
|
2024
Q3 | $46.5M | Buy |
168,923
+76,315
| +82% | +$19.9M | 0.1% | 251 |
|
|
2024
Q2 | $22.5M | Sell |
92,608
-55,896
| -38% | -$8.82M | 0.05% | 382 |
|
|
2024
Q1 | $22.2M | Buy |
148,504
+11,363
| +8% | +$1.9M | 0.05% | 393 |
|
|
2023
Q4 | $26.3M | Buy |
+137,141
| New | +$23.4M | 0.07% | 331 |
|
|
2023
Q3 | – | Sell |
-4,060
| Closed | -$771K | – | 2093 |
|
|
2023
Q2 | $771K | Sell |
4,060
-42,245
| -91% | -$8.38M | ﹤0.01% | 1227 |
|
|
2023
Q1 | $9.28M | Sell |
46,305
-804
| -2% | -$169K | 0.02% | 564 |
|
|
2022
Q4 | $11.2M | Buy |
+47,109
| New | +$10M | 0.03% | 514 |
|
|
2022
Q1 | – | Sell |
-992,180
| Closed | -$168M | – | 2176 |
|
|
2021
Q4 | $168M | Buy |
992,180
+33,360
| +3% | +$6.2M | 0.31% | 83 |
|
|
2021
Q3 | $181M | Sell |
958,820
-23,258
| -2% | -$4.36M | 0.34% | 67 |
|
|
2021
Q2 | $166M | Sell |
982,078
-6,640
| -0.7% | -$973K | 0.31% | 75 |
|
|
2021
Q1 | $140M | Buy |
988,718
+253,244
| +34% | +$38.1M | 0.27% | 84 |
|
|
2020
Q4 | $95.6M | Buy |
735,474
+172,563
| +31% | +$23M | 0.2% | 134 |
|
|
2020
Q3 | $82M | Sell |
562,911
-13,558
| -2% | -$1.93M | 0.19% | 128 |
|
|
2020
Q2 | $85.4M | Sell |
576,469
-15,547
| -3% | -$2.1M | 0.21% | 113 |
|
|
2020
Q1 | $64.4M | Sell |
592,016
-142,346
| -19% | -$16.4M | 0.19% | 122 |
|
|
2019
Q4 | $84.6M | Buy |
734,362
+178,973
| +32% | +$17.8M | 0.19% | 125 |
|
|
2019
Q3 | $44.7M | Buy |
555,389
+88,240
| +19% | +$6.98M | 0.11% | 213 |
|
|
2019
Q2 | $33.9M | Sell |
467,149
-60,002
| -11% | -$4.6M | 0.08% | 254 |
|
|
2019
Q1 | $49.3M | Buy |
527,151
+900
| +0.2% | +$75.3K | 0.12% | 189 |
|
|
2018
Q4 | $38.4M | Sell |
526,251
-125,116
| -19% | -$9.62M | 0.1% | 217 |
|
|
2018
Q3 | $57M | Buy |
651,367
+48,117
| +8% | +$4.84M | 0.13% | 178 |
|
|
2018
Q2 | $59.4M | Buy |
603,250
+202,207
| +50% | +$20.1M | 0.17% | 115 |
|
|
2018
Q1 | $47.8M | Sell |
401,043
-228,037
| -36% | -$29.4M | 0.14% | 128 |
|
|
2017
Q4 | $79.9M | Buy |
629,080
+457,913
| +268% | +$57.5M | 0.23% | 88 |
|
|
2017
Q3 | $20.1M | Buy |
171,167
+108,874
| +175% | +$9.29M | 0.06% | 259 |
|
|
2017
Q2 | $4.97M | Buy |
62,293
+52,293
| +523% | +$3.34M | 0.01% | 574 |
|
|
2017
Q1 | $513K | Hold |
10,000
| – | – | ﹤0.01% | 1321 |
|
|
2016
Q4 | $374K | Sell |
10,000
-503
| -5% | -$21.1K | ﹤0.01% | 1388 |
|
|
2016
Q3 | $712K | Sell |
10,503
-58
| -0.5% | -$4.09K | ﹤0.01% | 1192 |
|
|
2016
Q2 | $586K | Buy |
+10,561
| New | +$665K | ﹤0.01% | 1238 |
|
|
2013
Q3 | – | Sell |
-562
| Closed | -$17K | – | 1748 |
|
|
2013
Q2 | $17K | Buy |
+562
| New | +$15K | ﹤0.01% | 1656 |
|
Other funds holding ALNY
Federated Hermes's ALNY Position: Q2 2026 in Review
Federated Hermes increased its Alnylam Pharmaceuticals (ALNY) stake by 4.7% in Q2 2026, buying an estimated $9.68M and bringing the position to 719,905 shares worth $217M. The position accounts for 0.31% of the portfolio, ranked #78.
Federated Hermes first reported a position in ALNY in Q2 2013 and has held it in 38 quarters since. The position peaked at $251M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- Federated Hermes held 719,905 shares of Alnylam Pharmaceuticals worth $217M as of Q2 2026.
- Federated Hermes bought 32,089 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.68M.
- Alnylam Pharmaceuticals made up 0.31% of Federated Hermes's portfolio in Q2 2026, its #78 holding.
- Federated Hermes first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
- Federated Hermes's Alnylam Pharmaceuticals position peaked at $251M in Q3 2025.
- 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.